High-profile jobs breathe dollars 6m into Ruder healthcare

NEW YORK: Ruder Finn’s healthcare practice has added dollars 6 million in new accounts over the last few months, revitalizing the agency’s business in the arthritis, cardiology and dermatology sectors.

NEW YORK: Ruder Finn’s healthcare practice has added dollars 6 million in new accounts over the last few months, revitalizing the agency’s business in the arthritis, cardiology and dermatology sectors.

NEW YORK: Ruder Finn’s healthcare practice has added dollars 6

million in new accounts over the last few months, revitalizing the

agency’s business in the arthritis, cardiology and dermatology

sectors.



Among the wins were two Novartis pharmaceuticals, Impact (a liquid

nutritional supplement) and Zelmac (a treatment for irritable bowel

syndrome). Other companies who have entrusted at least a piece of their

business to the agency include Pfizer, Pharmanex, Searle and Solvay

Pharmaceuticals.



The wins represent validation for RF executive vice president and

director of healthcare Paul McDade, who joined the agency a little over

a year ago and was charged with revitalizing the practice.



He oversaw a restructuring within the healthcare operation, and has

stressed an organic growth philosophy that seems to be paying off.

Witness the new business from Pfizer - RF had quietly been one of the

key parties behind the Viagra launch.



’These clients put us at a 30% growth rate for the first half of 1999,’

he said. ’It’s a testament to the talent and commitment of our

healthcare professionals worldwide.’



Healthcare is RF’s largest practice area. The firm’s 1998 billings

within the sector of dollars 18.1 million placed it sixth on PRWeek’s

annual ranking of healthcare PR practices.



McDade previously worked for Edelman healthcare.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.